← Eichor
Study identifier: NCT06262620 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Comparison of EBUS-TBNA, TBMC Via a Tunnel, and TBFB Via a Tunnel in Diagnosing Mediastinal Lymphadenopathy.

Condition: Lymphadenopathy Hilar · Lymphadenopathy Mediastinal  ·  Sponsor: China-Japan Friendship Hospital

PhaseNA
Planned participants552
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this prospective, multi-centre, randomised controlled clinical study is to compare the diagnostic yield and safety of the three biopsy techniques (EBUS-TBNA, EBUS-TBMC via a tunnel, and EBUS-TBFB via a tunnel) in mediastinal/hilar lymph node biopsies. Participants will divided into EBUS-TBNA group, EBUS-TBMC via a tunnel group, and EBUS-TBFB via a tunnel group at a 1:1:1 ratio by using central, computerized random sequence, and then undertake EBUS-TBNA, EBUS-TBMC via a tunnel, or EBUS-TBFB according to the group. Researchers will compare the diagnostic yield and incidence of adverse events of the three biopsy techniques.

This description comes directly from the study's public registry record.

Talk to the study team

Gang Hou, MD  ·  010-84205729  ·  hougangcmu@163.com

Mingming Deng, PhD  ·  +86 18801336854  ·  isdeng@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

China-Japan Friendship HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06262620